Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis

Lancet

Volumn 352, Issue 9127, 1998, Pages 522-527

  Salam, Mohammed Abdus ^a   Dhar, Ujjwal ^a   Khan, Wasif Ali ^a   Bennish, Michael L ^b,c  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; ARTHRALGIA; ARTHROPATHY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIGELLA; SHIGELLOSIS;

EID: 0032529314     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11457-X     Document Type: Article

References (30)

1. 1 Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990; 264: 1438-40.
2. 2 Burkhardt JE, Walterspiel SN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25: 1196-204.
3. 3 Salam MA, Bennish ML. Therapy for shigellosis 1: randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113: 901-07.
4. 4 Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children; retrospective matched controlled study for cartilage toxicity. Infection 1987; 15: 165-68.
5. 5 Hampel B, Hullman R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997; 16: 127-29.
6. 6 Cruciani M, Concia E, Navarra A, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children: prospective randomized study. Infection 1989; 17: 65-69.
7. 7 Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997; 16: 97-105.
8. 8 Freifeld A, Pizzo P. Use of fluroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 1997; 16: 140-46.
9. 9 Lang R, Goshen S, Rass-Rothschild A, et al. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr Infect Dis J 1992; 11: 925-29.
10. 10 Dagan R, Schlaeffer F, Einhorn M. Parenteral fluroquinolones in children with life-threatening infections. Infection 1990; 18: 237-38.
11. 11 Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis II: randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162: 711-16.
12. 12 Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139. Lancet 1996; 348: 296-300.
13. 13 Bavdekar A, Chaudhari M, Bhave S, Pandit A. Ciprofloxacin in typhoid fever. Indian J Pediatr 1991; 58: 335-39.
14. 14 Tran TH, Bethell DB, Nguyen TT, et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995; 20: 917-23.
15. 15 Gendrel D, Moreno JL, Nduwimana M, Baribwira C, Raymond J. One-dose treatent with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis 1997; 24: 83.
16. 16 Pear R. President to order drug makers to conduct pediatric studies. New York Times, August 13, 1997: section A, 17.
17. 17 Fontaine O. Antibiotics in the management of shigellosis in children: what role for the quinolones? Rev Infect Dis 1989; 11 (suppl 5): S1145-49.
18. 18 Bennish ML, Wojtyniak BJ. Mortality due to shigellosis: community and hospital data. Rev Infect Dis 1991; 13 (suppl 4): S245-51.
19. 19 Bennish ML, Levy SB. Antimicrobial resistance of enteric pathogens. In: Blaser JM, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. New York: Raven Press, 1995: 1499-523.
20. 20 Bennish ML, Salam MA, Khan WA, Khan AM. Therapy of shigellosis III: comparison of one-or two-dose ciprofloxacin with standard 5-day therapy: a randomized, blinded trial. Ann Intern Med 1992; 117: 727-34.
21. 21 Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis IV: cefixime ineffective in shigellosis in adults. Ann Intern Med 1995; 123: 505-08.
22. 22 Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis V: comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997; 126: 697-703.
23. 23 Hewitt W, Vincent S. Theory and application of microbiologic assay. San Diego: Academic Press, 1989.
24. 24 Krol GJ, Beck GW, Benham T. HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. J Pharm Biomed Anal 1995; 14: 181-90.
25. 25 Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982; 3: 345-53.
26. 26 Peltola H, Väärälä M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992; 36: 1086-90.
27. 27 Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16: 112-17.
28. 28 Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of anti-pseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging: Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997; 16: 572-78.
29. 29 Ronsmans C, Bennish ML. Current practices for treatment of dysentery in rural Bangladesh. Rev Infect Dis 1991; 13 (suppl 4): S351-56.
30. 30 Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996; 5: 201-06.